Çoklu Antibiyotik Direnci Gösteren Bakterilere Karşı Geliştirilen Yeni Antibiyotikler; Dalbavansin, Telavansin ve Oritavansin

Year 2020, Volume: 13 Issue: 2, 45 - 54, 28.08.2020

Oruc Yunusoğlu , Mehmet Berköz , Yavuz Yardım

Abstract

Antibiyotiklerin rasyonel kullanılmaması hem gelişmekte olan ülkelerde hem de gelişmiş olan ülkelerde çok ciddi tıbbi ve ekonomik problemler oluşturmaktadır. Günümüzde antibiyotiklerin rasyonel kullanılmamasının en önemli sorunlarından biri kullanılan çoğu antibiyotiklere karşı bakterilerin direnç geliştirmesidir. Bakterilerin direnç geliştirmesi yeni antibiyotiklerin geliştirilmesini mecbur kılmaktadır. Günümüzde yaygın olarak kullanılan glikopeptid yapıda olan, vankomisin ve teikoplanin uzun yıllardır kullanılmaktadır. Fakat son zamanlar bu antibiyotiklere karşı direnç geliştiği tespit edilmiştir. Bundan dolayı benzer endikasyonlarda kullanılabilecek glikopeptidlerin üst sınıfı olan lipoglikopeptidler geliştirilmiştir. Dalbavansin, telavansin ve oritavansin Amerikan Gıda ve İlaç Kurumu’ndan (FDA) yeni onayı almış lipoglikopeptid yapıta antibiyotiklerdir. Bu yeni antibiyotikler, vankomisin ve teikoplanine direnç gelişmiş bakteriyel enfeksiyonların tedavisinde kullanılmaktadır. Bu yazıda antibiyotik direncinden, vankomisine ve teikoplanine direnç geliştirmiş bakterilerden ve FDA tarafından onay almış lipoglikopeptid yapılı yeni antibiyotikler ile ilgili güncel bilgi sunulmuştur.

Keywords

Dalbavansin, telavansin, oritavansin, direnç, lipoglikopeptidler

Dalbavancin, Telavancin and Oritavancin: Novel Antibiotics Developed Against Multiple Antibiotic Resistant Bacteria

Abstract

The irrational use of antibiotics poses serious medical and economic problems in both developing and developed countries. One of the most serious problems of irrational use of antibiotics is the development of bacterial resistance against most antibiotics in the clinical use which leads to requirement of the search for novel antibiotics. Vancomycin and teicoplanin, which are commonly used glycopeptides, have been used for many years. However, bacterial resistance to these antibiotics has recently been developed. Therefore, lipoglycopeptides, which are classified as superclass of glycopeptides, have been developed for utilizing in similar indications. Dalbavancin, telavancin and oritavancin belong to the class of lipoglycopeptide antibiotics that have recently been approved by the American Food and Drug Administration (FDA). These novel antibiotics are used in the treatment of the bacterial infections ressistant to vancomycin and teicoplanin. In this article, an information regarding the development of bacterial resistance against vancomycin and teicoplanin as well as FDA approved lipoglycopeptide antibiotics was provided.

Keywords

Dalbavancin, telavancin, oritavancin, resistance, lipoglycopeptides

References

• Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017; 23 : 697-703.
• Almarzoky Abuhussain SS, Goodlet KJ, Nailor MD, Nicolau DP. Optimizing skin and skin structure infection outcomes: considerations of cost of care. Expert Rev Pharmacoecon Outcomes Res. 2018; 18: 235-244.
• Aminov RI1. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010; doi: 10.3389/fmicb.2010.00134.
• (ANONİM 1) http://www.tuba.gov.tr/upload/files/Antibiyotik_201710.pdf
• (ANONİM 2) https://www.cdc.gov/drugresistanceındex.html
• (ANONİM 3) http://www.tepav.org.tr/uploadfiles/15047747351.Turkiye___de_Antimikrobiyal_Direnc___Ekonomik_Degerlendirme_ve_Oneriler.pdf
• (ANONİM 4) http://www.who.int/news-roomdetail/27-022017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
• Bell AM, King ST, Barber KE, Adcock KG, Wagner JL, Stover KR. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides. Nurse Pract. 2017; 42 :1-6.
• Bell AM, King ST, Barber KE, Adcock KG, Wagner JL, Stover KR. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections. Nurse Pract. 2018; 43: 31-37.
• Lee Ventola C. The Antibiotic Resistance Crisis. Pharmacy and Therapeutics. 2015; 40: 277-283
• Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000; 13: 686-707.
• Davies J1. Where have All the Antibiotics Gone? Can J Infect Dis Med Microbiol. 2006 ;17: 287-90.
• Frieri M1, Kumar K2, Boutin A3. Antibiotic resistance. J Infect Public Health. 2017; 10: 369-378.
• Hahn AW, Jain R, Spach DH. New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents. Med Clin North Am. 2016; 100: 911-26.
• Hakim A, Braun H, Thornton D, Strymish J. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report. Int J Infect Dis. 2019; 91: 202-205.
• Holmes NE1, Tong SY2, Davis JS2, van Hal SJ3. Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med. 2015; 36: 17-30.
• Jaffa RK, Pillinger KE, Roshdy D, Isip JA, Pasquale TR. Novel developments in the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2019. 20: 1493-1502.
• Jagan N, Pendru R, Jyothinath K. Efficacy of Dalbavancin and Telavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections. Maedica (Buchar). 2018. 13: 208-212.
• Klinker KP, Borgert SJ. Beyond Vancomycin: The Tail of the Lipoglycopeptides. Clin Ther. 2015. 37: 2619-36.
• Koulenti D, Xu E, Mok IYS, Song A, Karageorgopoulos DE, Armaganidis A, Lipman J, Tsiodras S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms. 2019, doi: 10.3390/microorganisms7080270.
• Marcone GL, Binda E, Berini F, Marinelli F. Old and new glycopeptide antibiotics: From product to gene and back in the post-genomic era. Biotechnol Adv. 2018; 36: 534-554.
• McGuinness WA, Malachowa N, DeLeo FR. Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med. 2017; 23: 269-281.
• Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs. Open Forum Infect Dis. 2019; doi: 10.1093/ofid/ofz274.
• Oravcova V, Svec P, Literak I. Vancomycin-resistant enterococci with vanA and vanB genes in Australian gulls. Environ Microbiol Rep. 2017; 9: 316-318.
• Rustam A. History of antimicrobial drug discovery: Major classes and health impact. Biochemical Pharmacology. 2017; 133: 4-19.
• Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers. Antimicrob Agents Chemother. 2018; doi: 10.1128/AAC.02397-17.
• Siang Yong Tan, Yvonne Tatsumura. Alexander Fleming (1881–1955): Discoverer of penicillin. Singapore Med J. 2015; 56: 366–367.
• Trueba F, Garrabe E, Hadef R, Fabre R, Cavallo JD, Tsvetkova K, Chesneau O. High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol. 2006; 44: 1922-3.
• Yim J, Smith JR, Rybak MJ. Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence. Pharmacotherapy. 2017; 37: 579-592.